Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors.

Gusach A, Luginina A, Marin E, Brouillette RL, Besserer-Offroy É, Longpré JM, Ishchenko A, Popov P, Patel N, Fujimoto T, Maruyama T, Stauch B, Ergasheva M, Romanovskaia D, Stepko A, Kovalev K, Shevtsov M, Gordeliy V, Han GW, Katritch V, Borshchevskiy V, Sarret P, Mishin A, Cherezov V.

Nat Commun. 2019 Dec 6;10(1):5573. doi: 10.1038/s41467-019-13348-2.

2.

Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs.

Luginina A, Gusach A, Marin E, Mishin A, Brouillette R, Popov P, Shiriaeva A, Besserer-Offroy É, Longpré JM, Lyapina E, Ishchenko A, Patel N, Polovinkin V, Safronova N, Bogorodskiy A, Edelweiss E, Hu H, Weierstall U, Liu W, Batyuk A, Gordeliy V, Han GW, Sarret P, Katritch V, Borshchevskiy V, Cherezov V.

Sci Adv. 2019 Oct 9;5(10):eaax2518. doi: 10.1126/sciadv.aax2518. eCollection 2019 Oct.

3.

Apelin-13 Regulates Vasopressin-Induced Aquaporin-2 Expression and Trafficking in Kidney Collecting Duct Cells.

Boulkeroua C, Ayari H, Khalfaoui T, Lafrance M, Besserer-Offroy É, Ekindi N, Sabbagh R, Dumaine R, Lesur O, Sarret P, Chraibi A.

Cell Physiol Biochem. 2019;53(4):687-700. doi: 10.33594/000000165.

4.

Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13).

Sousbie M, Vivancos M, Brouillette RL, Besserer-Offroy É, Longpré JM, Leduc R, Sarret P, Marsault É.

J Med Chem. 2018 Aug 23;61(16):7103-7115. doi: 10.1021/acs.jmedchem.8b00175. Epub 2018 Aug 13.

PMID:
30035538
5.

Label-free cell signaling pathway deconvolution of angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIIIIV responses.

Lavenus S, Simard É, Besserer-Offroy É, Froehlich U, Leduc R, Grandbois M.

Pharmacol Res. 2018 Oct;136:108-120. doi: 10.1016/j.phrs.2018.06.027. Epub 2018 Jun 28.

PMID:
29959993
6.

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms.

St-Pierre D, Cabana J, Holleran BJ, Besserer-Offroy É, Escher E, Guillemette G, Lavigne P, Leduc R.

Biochem Pharmacol. 2018 Aug;154:104-117. doi: 10.1016/j.bcp.2018.04.021. Epub 2018 Apr 20.

PMID:
29684376
7.

In Search of the Optimal Macrocyclization Site for Neurotensin.

Sousbie M, Besserer-Offroy É, Brouillette RL, Longpré JM, Leduc R, Sarret P, Marsault É.

ACS Med Chem Lett. 2018 Jan 29;9(3):227-232. doi: 10.1021/acsmedchemlett.7b00500. eCollection 2018 Mar 8.

8.

The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment.

Besserer-Offroy É, Bérubé P, Côté J, Murza A, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Marsault É, Sarret P.

Pharmacol Res. 2018 May;131:7-16. doi: 10.1016/j.phrs.2018.02.032. Epub 2018 Mar 9.

PMID:
29530600
9.

Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues.

Fanelli R, Floquet N, Besserer-Offroy É, Delort B, Vivancos M, Longpré JM, Renault P, Martinez J, Sarret P, Cavelier F.

J Med Chem. 2017 Apr 27;60(8):3303-3313. doi: 10.1021/acs.jmedchem.6b01848. Epub 2017 Apr 10.

PMID:
28368584
10.

The signaling signature of the neurotensin type 1 receptor with endogenous ligands.

Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, Leduc R.

Eur J Pharmacol. 2017 Jun 15;805:1-13. doi: 10.1016/j.ejphar.2017.03.046. Epub 2017 Mar 22.

PMID:
28341345
11.

Structure-activity relationship of novel macrocyclic biased apelin receptor agonists.

Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

Org Biomol Chem. 2017 Jan 4;15(2):449-458. doi: 10.1039/c6ob02247b.

PMID:
27924341
12.

Design, synthesis, and biological evaluation of CXCR4 ligands.

Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

Org Biomol Chem. 2016 Nov 2;14(43):10298-10311.

PMID:
27752700
13.

Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.

Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.

PMID:
27434274
14.

Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2.

Thomas JB, Vivancos M, Giddings AM, Wiethe RW, Warner KR, Murza A, Besserer-Offroy É, Longpré JM, Runyon SP, Decker AM, Gilmour BP, Sarret P.

ACS Chem Neurosci. 2016 Sep 21;7(9):1225-31. doi: 10.1021/acschemneuro.6b00097. Epub 2016 Jul 13.

PMID:
27359371
15.

Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.

Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpré JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

J Med Chem. 2016 Apr 14;59(7):2962-72. doi: 10.1021/acs.jmedchem.5b01549. Epub 2016 Mar 30.

PMID:
26986036
16.

Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.

Fanelli R, Besserer-Offroy É, René A, Côté J, Tétreault P, Collerette-Tremblay J, Longpré JM, Leduc R, Martinez J, Sarret P, Cavelier F.

J Med Chem. 2015 Oct 8;58(19):7785-95. doi: 10.1021/acs.jmedchem.5b00841. Epub 2015 Sep 16.

PMID:
26348111
17.

C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action.

Murza A, Besserer-Offroy É, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, Marsault É.

J Med Chem. 2015 Mar 12;58(5):2431-40. doi: 10.1021/jm501916k. Epub 2015 Feb 24.

PMID:
25668242
18.

Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.

Demeule M, Beaudet N, Régina A, Besserer-Offroy É, Murza A, Tétreault P, Belleville K, Ché C, Larocque A, Thiot C, Béliveau R, Longpré JM, Marsault É, Leduc R, Lachowicz JE, Gonias SL, Castaigne JP, Sarret P.

J Clin Invest. 2014 Mar;124(3):1199-213. doi: 10.1172/JCI70647. Epub 2014 Feb 17.

19.

Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability.

Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault É.

ChemMedChem. 2012 Feb 6;7(2):318-25. doi: 10.1002/cmdc.201100492. Epub 2011 Dec 13.

PMID:
22170700

Supplemental Content

Loading ...
Support Center